Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry

This analysis of Canadian registry data reports improvements in all disease parameters over time in patients with psoriatic arthritis treated with infliximab (n=111), golimumab (281) and ustekinumab 70), with severe adverse events reported in 19.8%, 8.5% and 5.7%, respectively.

Source:

BMJ Open